National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.
about
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemiaThe 1st and the 2nd Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and updateTriglyceride-rich lipoproteins as a causal factor for cardiovascular diseaseStatin non-adherence: clinical consequences and proposed solutionsPrescription omega-3 fatty acid products: considerations for patients with diabetes mellitusDyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategiesNiacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.Challenges in the Diagnosis and Treatment of Homozygous Familial HypercholesterolemiaPathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention GuidelinesVascular Disease in Young Indians (20-40 years): Role of DyslipidemiaOverview of prescription omega-3 fatty acid products for hypertriglyceridemiaA Comparative Overview of Prescription Omega-3 Fatty Acid ProductsThe panorama of familial hypercholesterolemia in Latin America: a systematic review.Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin UseAccuracy of low-density lipoprotein cholesterol estimation at very low levels.Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant CholesterolLipid management in India: a nationwide, cross-sectional physician survey.Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potencyLow-density lipoprotein cholesterol of less than 70 mg/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real-life cohort in Thailand.Deciphering cholesterol treatment guidelines: a clinician's perspective.Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study.Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent EthylConsensus statement on the management of dyslipidemia in Indian subjects: A different perspective.Prevalence of dyslipidemia and associated factors among the hypertensive population from rural Northeast China.Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.Changes in Lipid Profile of Obese Patients Following Contemporary Bariatric Surgery: A Meta-Analysis.Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol: The Very Large Database oThe lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Association between serum non-high-density lipoprotein cholesterol and cognitive impairment in patients with acute ischemic strokeSalsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individualsNew insights of altered lipid profile in Fragile X Syndrome.Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.Dyslipidemia in the Arabian Gulf and its Impact on Cardiovascular Risk OutcomeStatins to improve cardiovascular outcomes in treated HIV infection.Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.Reduction in total recurrent cardiovascular events in acute coronary syndrome patients with low-density lipoprotein cholesterol goal <70 mg/dL: a real-life cohort in a developing country.Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series.Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database.
P2860
Q26738554-520D1CDE-08D9-4458-9832-16E471975B0DQ26740292-D2EDFA62-093F-47F1-9891-57C258727D14Q26745946-2F89521F-54A2-4A80-B197-BB155C332501Q26748560-9BE18729-8F63-4234-8193-FB8B7991DD07Q26752919-30009E27-9F7B-45A4-B359-F4F40BC56DD5Q26765157-FDC67BA3-EA6E-4837-BCBB-E0E42BEEC18AQ26766157-D6E61C94-C1E9-4E24-822C-D3553526B33EQ26787050-CD2C67AB-9C7C-42F6-BC9E-B7D15A8E1EEAQ26991787-D79547BF-CEB3-4064-819A-48531D3E07CAQ28066247-D6A68552-873F-4938-9B02-1B87EB267330Q28251391-0B6299D4-D700-4B81-872B-53CCC6477AF0Q28972330-2017F540-33EB-462F-99A1-4ED300A20FB9Q30244116-A4D1DC37-10D1-4C93-BEB5-26FAA5EB5577Q33572803-FD205C31-6C91-4718-9F9B-243ECC5D8743Q33587438-2ECEB876-BC17-49D4-9B5F-C4D31283BFDBQ33808620-A8B35541-13EC-4275-878F-CAC3E276026CQ33848771-F3E14E10-1C73-4D0B-842B-9B643729EF3AQ33868780-716D7E68-41C0-4B8F-8AF3-12AD5DBA78ECQ35043492-369941EB-12BA-4487-9605-8EA42FD07F6BQ35571771-1CE3804E-4BD6-4AC5-82BE-956FBF9C8DA2Q35600989-5BE7DCEC-6D43-49E9-BB2D-C58F3E0A6298Q35664325-2F0D40B7-DD8A-4B43-879D-6452EAB64AC2Q35689882-9BA4F03F-A00C-464A-81DD-814ED98C30A4Q35756633-8E8D4E77-7C9A-4633-A0FA-32767BFB583AQ35763959-1A21A8B4-4E43-450B-BA96-C6ED69DEDE28Q35847497-A68639EE-17A6-4594-8411-111024CC1BE1Q35916476-81194ED9-3127-4627-BA2F-1FED2E4C25F1Q35930085-1E7A26A4-E9C2-4C10-8103-9AD81223F3BDQ35998273-9DA8A973-ABE1-4C58-B3F2-B5FDF61C7C57Q36069577-98868DF6-D3A9-43AF-9E1C-A634ABC9F299Q36113273-275331FA-6FBA-4ED8-B02C-6F164A22DF90Q36124070-BDA1E0B7-3EA1-4125-838F-BB76978B36C6Q36320196-C2574516-1593-4EE0-88C2-612D939F3C70Q36368459-D4143A3A-566A-415E-B986-54B9B77B5462Q36373684-0C222FEC-E721-4281-BC85-1D00A69AEE50Q36399904-F89F6316-2095-43CF-B2D5-72460C0D4BCBQ36411986-A5A00A77-6AB8-422D-8BD2-8299A2078C01Q36658187-03B281BF-38A8-496B-931F-A1B8CE7B82BCQ36712679-B0711269-0DD6-43D0-AC1E-5053BD8F8FAAQ36823179-2CEE80F8-F229-4DCB-A16D-5E4FC9230D96
P2860
National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
National Lipid Association rec ...... a: part 1 - executive summary.
@ast
National Lipid Association rec ...... a: part 1 - executive summary.
@en
National Lipid Association rec ...... a: part 1 - executive summary.
@nl
type
label
National Lipid Association rec ...... a: part 1 - executive summary.
@ast
National Lipid Association rec ...... a: part 1 - executive summary.
@en
National Lipid Association rec ...... a: part 1 - executive summary.
@nl
prefLabel
National Lipid Association rec ...... a: part 1 - executive summary.
@ast
National Lipid Association rec ...... a: part 1 - executive summary.
@en
National Lipid Association rec ...... a: part 1 - executive summary.
@nl
P2093
P1476
National Lipid Association rec ...... a: part 1 - executive summary.
@en
P2093
Carl E Orringer
Don P Wilson
Edward A Gill
Harold E Bays
James M McKenney
Kevin C Maki
Matthew K Ito
Peter H Jones
Robert A Wild
Scott M Grundy
P304
P356
10.1016/J.JACL.2014.07.007
P407
P577
2014-07-15T00:00:00Z